Drugs / AMP-224
AMP-224
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02298946 | Nov 2014 → Jul 2016 | colorectal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01352884 | Mar 2011 → Nov 2013 | cancer | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMP-224 | “AMP-224, a B7-DC Fc fusion protein, binds to PD-1, an inhibitory receptor” NCT02298946 ↗ |
| Known as | Anti-pd-1 fusion protein amp-224 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297570 ↗ |
| Known as | GSK-2661380 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297570 ↗ |
| Action | Inhibit | “AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer” NCT02298946 ↗ |
| Modality | Protein / enzyme biologic | “AMP-224, a B7-DC Fc fusion protein, binds to PD-1, an inhibitory receptor” NCT02298946 ↗ |
| Route | Intravenous | “AMP-224 therapy will be given as an intravenous infusion” NCT02298946 ↗ |